Advanced Liver Cancer Market is segmented By Clinical Trials (Phase III, Phase II, Phase I), By Route of Administration (Oral, Intravenous), By Molecule Type (Small Molec ....
Market Size in USD
CAGR7.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.2% |
Market Concentration | Medium |
Major Players | Can-Fite BioPharma, Polaris Pharmaceuticals, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Exelixis |
The Global Advanced Liver Cancer Market is estimated to be valued at USD 3.4 Bn in 2024 and is expected to reach USD 9.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031. Major factors such as rising incidence of liver cancer worldwide along with growing geriatric population are expected to boost the growth of this market during the forecast period. Furthermore, increased R&D investments by key pharmaceutical players for the development of novel targeted drug therapies for advanced liver cancer will also contribute to market growth.
The market trend for Advanced Liver Cancer suggests high growth potential during the forecast period. Significant unmet needs exist in treating advanced liver cancer as the disease has a poor prognosis. Currently, only a few targeted drug options are available, thus leaving scope for various pharmaceutical companies to develop new drugs. Emerging areas such as immuno-oncology also provide opportunities for development of immunotherapies and combination therapies for advanced liver cancer. This will enable patients to benefit from novel treatment options and contribute to an increasing demand.